OBJECTIVE: In this study, we sought to investigate the effects of @entity22487 ( @entity6514 ) on @entity900 -induced apoptosis and growth inhibition in SKOV3 @entity43 cells. MATERIALS AND METHODS: Cells were treated with @entity6514 , @entity3003 , or both, the control group, and cell viability and growth inhibition assays were performed using the @entity98 method. Apoptosis was detected by flow cytometry analysis. Reverse transcription polymerase chain reaction and western blotting were used to monitor the mRNA and protein expression of the pro-apoptotic genes @entity589 and @entity522 and the anti-apoptotic gene @entity588 . The phosphorylation of @entity588 protein was monitored by western blotting. RESULTS: Cell viability was inhibited by all three treatments in a time-dependent manner. Importantly, the combination treatment resulted in significantly reduced cell growth compared with the other groups. The mRNA and protein expression of @entity589 and @entity522 were increased in the combination treatment group, and the expression of @entity588 was decreased in the combination treatment group as compared with the other two groups. The ratio of @entity589 to @entity588 mRNA in the combination treatment group was higher than that in the @entity3003 -treated group. Finally, phosphorylation of @entity588 protein was increased stronger in the combination treatment group compared with the @entity3003 -treated group. CONCLUSIONS: @entity6514 promoted the growth inhibitory and apoptosis-inducing effects of @entity902 -based agents in SKOV3 @entity43 cells. The mechanism mediating this effect may be related to the phosphorylation of @entity588 protein, which reduces the formation of dimers and, thereby, increases apoptosis. Moreover, @entity6514 promoted the mRNA and protein expression of @entity589 , thereby, increasing the @entity589 / @entity588 expression ratio and activating the mitochondrial apoptosis pathway.

Underlying mechanism of XXXX -induced apoptosis and growth arrest in SKOV3 human @entity43 cells.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity589 :: ('581', 'Gene') :: ['bax', 'Bax'] @entity522 :: ('836', 'Gene') :: ['caspase-3'] @entity588 :: ('596', 'Gene') :: ['bcl-2', 'Bcl-2'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity6514 :: ('MESH:D008623', 'Chemical') :: ['2-ME'] @entity22487 :: ('MESH:C022830', 'Chemical') :: ['2-methoxyestradiol'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity22487 :: (MESH:C022830,Chemical) :: ['2-methoxyestradiol']
